EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, has announced that the board of the Company has approved the issue of 24,999,999 new ordinary shares of 1p each in the Company at a price of 14p per share raising £3,500,000 for the Company.
Existing high net worth shareholders have subscribed to the Fundraising.
The net proceeds of the Fundraising will support the acceleration of the Company’s prostate cancer programme which involves the development and delivery of best-in-class diagnostic products and services.
Application has been made for the Subscription Shares to be admitted to trading on the AQSE Growth Market and the Subscription remains conditional on Admission. It is expected that Admission will take place on Friday, February 20, 2026.
This latest fundraising follows the Company’s announcement on October 20, 2025 that the Company secured up to £4 million funding for product development and commercial operations through a combination of the issue of 14,285,713 new ordinary shares of 1p each in the Company at a price of 14p per share to raise £2.0 million as well as the issue of a new convertible loan note (CLN) agreement for up to £2.0 million to Professor Sir Chris Evans, the Company’s founder and Chief Scientific Officer.
Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: “We are delighted that investors in the Company have once again reinforced their support for the work we are doing to provide game-changing diagnostic solutions for the early detection of prostate cancer. The need for innovation in this area has never been clearer as we have seen with the recent intense debate around screening for the disease.
“Men need better diagnostic solutions and we are making excellent progress in our cancer programmes particularly in prostate.”
Dr Mike Hudson, Chief Executive Officer of EDX Medical, commented: “This investment is another vote of confidence in our strategy of developing and providing class-leading diagnostic solutions with immediate clinical benefits- improving outcomes for patients and delivering value for healthcare providers.”
Total Voting Rights
In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, the Company hereby announces that following the Fundraising, it will have 411,594,583 Ordinary Shares in issue, each share carrying the right to one vote.
The above figure of 411,594,583 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
